Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia 1

Interventions

Cyclophosphamide 125fludarabine phosphate 116Busulfan 98Peripheral Blood Stem Cell Transplantation 88Filgrastim 73Antilymphocyte Serum 72Tacrolimus 67Cytarabine 67Cyclosporine 64Mycophenolic Acid 63Methotrexate 57Radiotherapy 54fludarabine 52Whole-Body Irradiation 52Melphalan 49Imatinib Mesylate 41Azacitidine 35Methylprednisolone 34Etoposide 33Cord Blood Stem Cell Transplantation 30Granulocyte Colony-Stimulating Factor 28sargramostim 26Thiotepa 26Decitabine 21Alemtuzumab 21Clofarabine 20thymoglobulin 19Stem Cell Transplantation 19nilotinib 18Interferon-alpha 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Tyrosine Kinase Inhibitors × Myeloid × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡